
Opinion|Videos|November 12, 2024
Fezolinetant in Focus: Key Findings From the SKYLIGHT Trials
Key Takeaways
- Fezolinetant's approval was based on SKYLIGHT 1, 2, and 4 trials, which were randomized, double-blind, and placebo-controlled.
- The trials focused on women with moderate to severe vasomotor symptoms, evaluating fezolinetant's safety and efficacy.
Panelists discuss the methodologies of the SKYLIGHT 1, SKYLIGHT 2, and SKYLIGHT 4 trials that supported the approval of fezolinetant for moderate to severe vasomotor symptoms (VMS) and examine the key safety and efficacy results derived from these studies.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- (SMITH) The approval of fezolinetant for moderate to severe VMS was based on the
SKYLIGHT 1 ,SKYLIGHT 2 , andSKYLIGHT 4 trials. Briefly describe the methodology of these studies. - (FIFFICK) What were the key safety and efficacy results from the SKYLIGHT studies?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Promises and Pitfalls of AI in Health Care
2
Texas Sues J&J, Kenvue for Alleged Deception in Acetaminophen Marketing
3
SCRI’s Vivek Subbiah, MD, Highlights Trials on Tumor-Agnostic Cancer Therapies During ESMO
4
With New OUD Diagnoses on the Rise, More Comprehensive Screenings Needed
5











































